{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:51:51Z","timestamp":1778125911962,"version":"3.51.4"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2018.00268","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T05:24:36Z","timestamp":1538025876000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":55,"title":["Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1\/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature"],"prefix":"10.3389","volume":"5","author":[{"given":"Coralie","family":"Zumelzu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Le Roux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Guyot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Aucouturier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Mignot-Grootenboer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Caux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"Maubec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Prost-Squarcioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on Mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","article-title":"Definitions and outcome measures for Mucous membrane pemphigoid: recommendations of an international panel of experts","volume":"72","author":"Murrell","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0923-1811(97)00067-4","article-title":"Analysis of antigens targeted by circulating IgG and IgA autoantibodies in 50 patients with cicatricial pemphigoid","volume":"17","author":"Murakami","year":"1998","journal-title":"J Dermatol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/1523-1747.ep12329728","article-title":"Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain","volume":"106","author":"Balding","year":"1996","journal-title":"J Invest Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0161-6420(89)32922-8","article-title":"Immunophenotypic analysis of the inflammatory infiltrate in ocular cicatricial pemphigoid. Further evidence for a T cell-mediated disease","volume":"96","author":"Sacks","year":"1989","journal-title":"Ophthalmology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/S0161-6420(90)32402-8","article-title":"Immunopathology of cicatricial pemphigoid affecting the conjunctiva","volume":"97","author":"Rice","year":"1990","journal-title":"Ophthalmology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0161-6420(93)31644-1","article-title":"The conjunctiva in acute and chronic Mucous membrane pemphigoid. An immunohistochemical analysis","volume":"100","author":"Bernauer","year":"1993","journal-title":"Ophthalmology"},{"key":"B11","first-page":"1449","article-title":"T-helper 17 lymphocytes in ocular cicatricial pemphigoid","volume":"15","author":"Lambiase","year":"2009","journal-title":"Mol Vis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"8112","DOI":"10.1167\/iovs.11-9322","article-title":"Profile of local interleukin expression in a cohort of ocular cicatricial pemphigoid patients","volume":"53","author":"Suelves","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.2353\/ajpath.2009.090579","article-title":"Conjunctival interleukin-13 expression in Mucous membrane pemphigoid and functional effects of interleukin-13 on conjunctival fibroblasts in vitro","volume":"175","author":"Saw","year":"2009","journal-title":"Am J Pathol"},{"key":"B14","first-page":"3","article-title":"Naturally occurring regulatory T cells in Mucous membrane pemphigoid lesions","volume":"18","author":"Torchia","year":"2009","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/j.1365-2133.2004.06219.x","article-title":"Rapid effector function of circulating NC16A-specific T cells in individuals with Mucous membrane pemphigoid","volume":"151","author":"Black","year":"2004","journal-title":"Br J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/1523-1747.ep12292701","article-title":"Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida","volume":"108","author":"B\u00e9dane","year":"1997","journal-title":"J Invest Dermatol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-3-662-45698-9_19","article-title":"Part II: Diagnostic tests - Ch 19. Electron microscopy and immunoelectron microscopy","volume-title":"Blistering Diseases- Clinical Features, Pathogenesis, Treatment","author":"Prost-Squarcioni","year":"2015"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3389\/fimmu.2018.01030","article-title":"Gliptin accountability in Mucous membrane pemphigoid induction in 24 Out of 313 patients","volume":"9","author":"Gaudin","year":"2018","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdermsci.2007.02.012","article-title":"A widening perspective regarding the relationship between anti-epiligrin cicatricial pemphigoid and cancer","volume":"47","author":"Sadler","year":"2007","journal-title":"J Dermatol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"484","DOI":"10.2340\/00015555-0506","article-title":"Two cases of anti-epiligrin cicatricial pemphigoid with and without associated malignancy","volume":"88","author":"Fukushima","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000243807","article-title":"Mucous membrane pemphigoid with antibodies to the beta(3) subunit of Laminin 332 in a patient with acute myeloblastic leukemia and graft-versus-host disease","volume":"219","author":"Takahara","year":"2009","journal-title":"Dermatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jaad.2009.09.013","article-title":"Mucous membrane pemphigoid with autoantibodies to all the laminin 332 subunits and fatal outcome resulting from liver cirrhosis and hepatocellular carcinoma","volume":"64","author":"Dainichi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1684\/ejd.2011.1360","article-title":"Anti-laminin-332 Mucous membrane pemphigoid associated with recurrent metastatic prostate carcinoma: hypothesis for a paraneoplastic phenomenon","volume":"21","author":"Young","year":"2011","journal-title":"Eur J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1365-2133.2011.10520.x","article-title":"A case of paraneoplastic pemphigus associated with triple malignancies in combination with antilaminin-332 Mucous membrane pemphigoid","volume":"166","author":"Yamada","year":"2012","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1346-8138.2012.01645.x","article-title":"Anti-laminin-332 Mucous membrane pemphigoid with autoantibodies to \u03b13, \u03b23 and \u03b32 subunits of laminin-332 as well as to BP230 and periplakin associated with adenocarcinoma from an unknown primary site","volume":"40","author":"Fukuchi","year":"2013","journal-title":"J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/S0140-6736(00)04971-0","article-title":"Anti-epiligrin cicatricial pemphigoid and relative risk for cancer","volume":"357","author":"Egan","year":"2001","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1346-8138.2004.tb00497.x","article-title":"A case of anti-epiligrin cicatricial pemphigoid associated with lung carcinoma and severe laryngeal stenosis: review of Japanese cases and evaluation of risk for internal malignancy","volume":"31","author":"Matsushima","year":"2004","journal-title":"J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamadermatol.2013.1434","article-title":"Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in Mucous membrane pemphigoid","volume":"149","author":"Bernard","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.oooo.2013.12.402","article-title":"Diagnosis of oral Mucous membrane pemphigoid by means of combined serologic testing","volume":"117","author":"Hayakawa","year":"2014","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"768","DOI":"10.2340\/00015555-2311","article-title":"Autoantibody profile of a cohort of 78 Italian patients with Mucous membrane pemphigoid: correlation between reactivity profile and clinical involvement","volume":"96","author":"Cozzani","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40257-016-0235-z","article-title":"Paraneoplastic pemphigus and autoimmune blistering diseases associated with neoplasm: characteristics, diagnosis, associated neoplasms, proposed pathogenesis, treatment","volume":"18","author":"Kartan","year":"2017","journal-title":"Am J Clin Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/CMR.0000000000000260","article-title":"Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/cup.12735","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma","volume":"43","author":"Mochel","year":"2016","journal-title":"J Cutan Pathol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/ajd.12484","article-title":"Bullous pemphigoid-like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab","volume":"57","author":"Lomax","year":"2016","journal-title":"Australas J Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","article-title":"Development of bullous pemphigoid during nivolumab therapy","volume":"2","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1111\/jdv.14179","article-title":"Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology","volume":"31","author":"Bandino","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/ced.13042","article-title":"Severe bullous pemphigoid associated with pembrolizumabtherapy for metastatic melanoma with complete regression","volume":"42","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1684\/ejd.2016.2959","article-title":"Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab","volume":"27","author":"Russo","year":"2017","journal-title":"Eur J Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1111\/ajd.12488","article-title":"Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma","volume":"58","author":"Parakh","year":"2017","journal-title":"Australas J Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1111\/jdv.14143","article-title":"Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor","volume":"31","author":"Kwon","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1111\/1346-8138.13940","article-title":"Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII","volume":"44","author":"Wada","year":"2017","journal-title":"J Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1111\/1346-8138.14043","article-title":"Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab","volume":"45","author":"Kuwatsuka","year":"2018","journal-title":"J Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/CJI.0000000000000210","article-title":"Bullous pemphigoid-like skin lesions and overt eosinophilia in a patient with melanoma treated with nivolumab: case report and review of the literature","volume":"41","author":"Anastasopoulou","year":"2018","journal-title":"J Immunother"},{"key":"B48","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/ddg.13411","article-title":"Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma","volume":"16","author":"Amber","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1111\/jdv.14579","article-title":"Three new cases of bullous pemphigoid during anti-PD-1 antibody therapy","volume":"32","author":"Le Naour","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16780","article-title":"Pembrolizumab-associated Mucous membrane pemphigoid in a Merkel cell carcinoma patient","author":"Haug","year":"2018","journal-title":"Br J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/archderm.134.9.1075","article-title":"Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French bullous study group","volume":"134","author":"Vaillant","year":"1998","journal-title":"Arch Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"pembrolizumab versus Ipilimumab in advanced melanoma","volume":"26","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4161\/onci.21335","article-title":"Targeting PD-1\/PD-L1 interactions for cancer immunotherapy","volume":"1","author":"Zitvogel","year":"2012","journal-title":"Oncoimmunology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/intimm\/dxp072","article-title":"PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells","volume":"21","author":"Wang","year":"2009","journal-title":"Int Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1001\/archderm.1996.03890270044006","article-title":"Drugs associated with bullous pemphigoid. A case-control study","volume":"132","author":"Bastuji-Garin","year":"1996","journal-title":"Arch Dermatol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/jcpt.12397","article-title":"Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database","volume":"41","author":"Garc\u00eda","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase-IV inhibitors, a risk factor for bullous pemphigoid. Retrospective multicenter case\u2013control study in France and Switzerland","volume":"78","author":"Benzaquen","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV-inhibitors: a case\/non-case study in the French pharmacovigilance database","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br J Dermatol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish Nationwide Registry Study","volume":"138","author":"Varpuluoma","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0738-081X(98)00008-X","article-title":"Drug-induced pemphigoid: bullous and cicatricial","volume":"16","author":"Vassileva","year":"1998","journal-title":"Clin Dermatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma","volume":"36","author":"Robert","year":"2017","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Th\u00e9rapie"},{"key":"B73","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2018.00268\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T04:59:28Z","timestamp":1605070768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2018.00268\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":73,"alternative-id":["10.3389\/fmed.2018.00268"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2018.00268","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]},"article-number":"268"}}